NCT00662636View on ClinicalTrials.gov

Dasatinib and Lapatinib Ditolsylate in Treating Patients With Advanced Solid Tumors That Cannot Be Removed By Surgery

PHASE1CompletedINTERVENTIONAL
Enrollment

27

Participants

Timeline

Start Date

August 31, 2008

Primary Completion Date

December 18, 2014

Study Completion Date

December 18, 2014

Conditions
Unspecified Adult Solid Tumor, Protocol Specific
Interventions
DRUG

dasatinib

Given orally

DRUG

lapatinib ditosylate

Given orally

OTHER

pharmacological study

Correlative study (cohort II only)

OTHER

laboratory biomarker analysis

Correlative study (cohort II only)

Trial Locations (3)

55905

Mayo Clinic, Rochester

85259

Mayo Clinic in Arizona, Scottsdale

32224-9980

Mayo Clinic in Florida, Jacksonville

Sponsors

Lead Sponsor

Mayo Clinic
All Listed Sponsors
collaborator

National Cancer Institute (NCI)

NIH

lead

Mayo Clinic

OTHER

NCT00662636 - Dasatinib and Lapatinib Ditolsylate in Treating Patients With Advanced Solid Tumors That Cannot Be Removed By Surgery | Biotech Hunter | Biotech Hunter